Investors scanning stocks to watch for the week ahead get a split signal from the latest insider disclosures: a weekend recap of Form 4 filings counted 17 insider sales against five purchases, with organic C-suite selling outpacing buying.

The largest transaction was a $274.8-million block sale at Medline by a director-level institutional shareholder. Other notable sales included Protagonist Therapeutics' CFO selling about $8.3 million, Gilead Sciences chairman and CEO Daniel O'Day selling about $2.2 million, and Clover Health's CEO selling 318,806 shares for about $1.3 million — part of a broader biotech and tech selling cluster that also touched PagerDuty, Extreme Networks and Dropbox.

On the buy side, the standout was PepsiCo director Robert Pohlad, who bought 184,646 shares on October 14 at an average $128.28 — about $23.7 million — increasing his stake by roughly 74 per cent, in a filing reported by MarketBeat. A Pedevco 10-per-cent-owner director bought about $1.91 million, a Gold.com 10-per-cent-owner director about $1.28 million, a First Guaranty Bancshares director about $822,000, and Sprinklr director Stephen Ward Jr. bought 150,000 shares for $850,500.

Insider filings are disclosures, not recommendations: sales can reflect diversification or pre-arranged plans, and purchases can still lose money. This round-up reports what was filed — it is market news, not a tip or advice to trade.